Actavis Generic OxyContin To Launch In 2014 Under Patent Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
Actavis can sell a generic version of Purdue’s abuse-deterrent formulation 11 years before patents on the formulation expire; the company will launch on Jan. 1 if FDA approves its ANDA, or launch an authorized generic in October if approval is delayed.